Hormonal
Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.
In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.
Dapiglutide (4 mg or 6 mg) for 12 weeks did not result in a statistically significant difference in bodyweight change compared with placebo in persons with obesity.
Why this rating
Randomized, double-blind, placebo-controlled trial, though small sample size (n=54) and short duration limit generalizability.
Source
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial
Casper K. Nielsen et al. · EClinicalMedicine · 2026
DOI 10.1016/j.eclinm.2026.103801
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →